[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553197":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":25,"studyPopulation":26,"armGroups":27,"interventions":39,"overallOfficials":68,"centralContacts":73,"locations":79,"responsibleParty":97,"collaborators":100,"id":104,"slug":21,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":112,"minAge":21,"maxAge":21,"enrollmentInfo":113,"targetDuration":21,"studyType":116,"phases":21,"briefSummary":117,"conditions":118,"keywords":21,"overallStatus":81,"whyStopped":21,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Vanderbilt-Ingram Cancer Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":21},[9,13,15,18],{"measure":10,"description":11,"timeFrame":12},"Impact of disease on adverse oncologic outcomes","Medical record review of Common Terminology Criteria for Adverse Events (CTCAEs)","Approximately six years",{"measure":14,"description":11,"timeFrame":12},"Impact of treatment on adverse oncologic outcomes",{"measure":16,"description":17,"timeFrame":12},"Impact of sociodemographic contributors on adverse oncologic outcomes","Patient-Reported Outcomes Measurement Information System (PROMIS) Scores",{"measure":19,"description":20,"timeFrame":12},"Impact of lifestyle contributors on adverse oncologic outcomes","Patient-reported outcome",null,{"allocation":21,"interventionModel":21,"interventionModelDescription":21,"primaryPurpose":21,"observationalModel":23,"timePerspective":24,"maskingInfo":21},"COHORT","PROSPECTIVE","* To evaluate the incidence and prevalence and the impact of disease, treatment, sociodemographic and lifestyle contributors on adverse oncologic outcomes (lack of response, recurrence) and non- oncologic outcomes (physical and psychosocial function, financial toxicity, short and long-term organ toxicity) and mortality in the cohort.\n* To evaluate the role of drug metabolism and DNA repair genes via functional polymorphisms, known toxicity associated polymorphisms and genetically predicted gene expression levels, as well as polygenic risk scores, on treatment efficacy, cancer therapy-induced normal tissue toxicity and mortality.\n* To identify genomic drivers of sarcoma and to use this information to develop personalized liquid biopsy assays for monitoring treatment response, recurrence, and minimal residual disease (MRD) and mortality.\n* Evaluate family functioning, psychosocial wellbeing, and financial toxicity.\n\nOUTLINE: This is an observational study.\n\nPatients monitor physical activity, sedentary behavior, heart rate and sleep wearing a FitBit device, undergo blood urine, stool and\u002For saliva sample collection, complete surveys and have medical records reviewed throughout study.","Patients at any age with a history of sarcoma, with or without evidence of a persistent disease and parent\u002Fcaregiver of pediatric patients and siblings of patients 8 years or older",[28],{"label":29,"type":21,"description":30,"interventionNames":31},"Observational","Patients monitor physical activity, sedentary behavior, heart rate and sleep wearing a FitBit device, undergo blood urine, stool and\u002For saliva sample collection, complete surveys and have medical records reviewed throughout study.",[32,33,34,35,36,37,38],"Other: Surveys","Other: Blood Collection","Other: Saliva Collection","Other: Urine Collection","Other: Stool Collection","Other: Tissue collection","Other: Physical Activity Monitoring",[40,44,48,52,56,60,64],{"type":6,"name":41,"description":42,"armGroupLabels":43,"otherNames":21},"Surveys","Complete surveys",[29],{"type":6,"name":45,"description":46,"armGroupLabels":47,"otherNames":21},"Blood Collection","Undergo blood collection",[29],{"type":6,"name":49,"description":50,"armGroupLabels":51,"otherNames":21},"Saliva Collection","Undergo salvia collection",[29],{"type":6,"name":53,"description":54,"armGroupLabels":55,"otherNames":21},"Urine Collection","Undergo urine collection",[29],{"type":6,"name":57,"description":58,"armGroupLabels":59,"otherNames":21},"Stool Collection","Undergo stool collection",[29],{"type":6,"name":61,"description":62,"armGroupLabels":63,"otherNames":21},"Tissue collection","Undergo tissue collection",[29],{"type":6,"name":65,"description":66,"armGroupLabels":67,"otherNames":21},"Physical Activity Monitoring","FitBit will be worn to track physical activity",[29],[69],{"name":70,"affiliation":71,"role":72},"Debra Friedman, MD","Vanderbilt University\u002FIngram Cancer Center","PRINCIPAL_INVESTIGATOR",[74],{"name":75,"role":76,"phone":77,"phoneExt":21,"email":78},"Vanderbilt-Ingram Services for Timely Access","CONTACT","800-811-8480","cip@vumc.org",[80],{"facility":71,"status":81,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"RECRUITING","Nashville","Tennessee","37203","United States","US",{"type":88,"coordinates":89},"Point",[90,91],-86.78444,36.16589,{"lat":91,"lon":90},[94,96],{"name":95,"role":76,"phone":77,"phoneExt":21,"email":78},"Vanderbilt-Ingram Service for Timely Access",{"name":70,"role":72,"phone":21,"phoneExt":21,"email":21},{"type":72,"investigatorFullName":98,"investigatorTitle":99,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Debra Friedman","Professor of Pediatrics (Pediatric Hematology and Oncology)",[101],{"name":102,"class":103},"National Cancer Institute (NCI)","NIH","100553197",false,"NCT06482957","Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan","CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan","CAUSAL","Patients at any age with a history of sarcoma, with or without evidence of a persistent disease\n\n• For pediatric patients\n\n* Parent\u002Fprimary caregiver of patient\n* Sibling of patient aged 8 years or older",true,"ALL",{"count":114,"type":115},2100,"ESTIMATED","OBSERVATIONAL","This study evaluates the impact that a sarcoma diagnosis and treatment have had on patients over time.",[119],"Sarcoma","2025-09-15",{"date":122,"type":123},"2025-09-19","ACTUAL",{"date":125,"type":123},"2022-04-01",{"date":127,"type":115},"2029-04",{"name":5,"class":6},1]